Navigation Links
O2h and Hypoxium Announce an Agreement to Offer Hypoxium's Specialised In Vitro, Cell-Based Oncology Assays via O2h's Biology Affiliate Program
Date:6/25/2009

CAMBRIDGE, England, June 25 /PRNewswire/ -- O2h has initiated a networked approach towards being a full service discovery services company at the forefront of drug discovery research. O2h has established a new biology lab on-site in Ahmedabad, India offering physio-chemical and CYP450 assays.

O2h announces the first of its Biology Affiliate Partnership with Hypoxium Ltd. UK. Hypoxium has specialist capabilities in in vitro, cell-based oncology assays which will now be available in a seamless integration with the existing assays performed on-site by O2h.

Sunil Shah, CEO of O2h said "The focus of our biology strategy is to deliver seamless drug discovery via core centres of excellence. We are very happy to bring on board Hypoxium as an affiliate so O2h can now support its clients with oncology focused cell biology assays.

Dan Cowell, CEO of Hypoxium, said: "Working with O2h is an excellent fit with our strategy of supporting drug discovery research in a collaborative manner. It allows O2h clients access to focused cell biology via their existing project manager, yet retains transparent communication with the scientific team responsible for each area."

About O2h

O2h is a 4+ year old discovery services company with project offices in Cambridge, UK and research labs in Ahmedabad, India. Indian operations provide a high level of discovery expertise while UK office provides project management support. Current clients of O2h include several top 20 pharmaceutical and biotechnology companies in the US, Europe and Japan. O2h adheres to the highest standards of performance with a particular emphasis on rapid interactive communications and delivery speed. Services provided by O2h include FTE-based synthetic chemistry, medicinal chemistry, computational chemistry, full services lab-units and ADME. More details at http://www.o2h.com.

About Hypoxium

Based in Cambridge UK, Hypoxium was formed in October 2006 with the sole intention of providing comprehensive, high quality and affordable custom cell biology research services within the oncology therapeutic area. Hypoxium's goal is to provide scientifically driven and industry focused pre-clinical solutions, to assist in the development of novel therapies for oncology. Hypoxium can support projects from proof-of concept through to pre-clinical evaluation of new chemical entities. Since its formation, Hypoxium has attracted a wide range of clients and successfully delivered results that have significantly contributed to their discovery programs. More details at http://www.hypoxium.com.

    O2h Contact: Ekta Ahuja
    Email: info@o2h.com

    Hypoxium Contact: Dan Cowell
    Email: info@hypoxium.com


'/>"/>
SOURCE O2h and Hypoxium
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. OmniComm Systems Announces Acquisition of EDC Business of eResearchTechnology
2. Healthy Advice Networks Announces Improved Patient Outcomes in Physicians Offices with Healthy Advice Programs
3. Spherix Announces Termination of Arla License Agreement
4. Spherix Announces Full-Scale Production of Pharmaceutical Tagatose
5. Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-601 Repositioned Drug for Epilepsy
6. Sigma-Aldrich and Atlas Antibodies Announce 2,300 New, Highly Validated Prestige Antibodies(RM)
7. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
8. Dragon Pharma Announces Results of 2009 Annual General Meeting
9. BRAHMS, Cezanne and Lumiphore Announce Partnership for Diagnostic Tests
10. Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer
11. Isolagen, Inc. Announces Receipt of Interim Order from Bankruptcy Court Approving DIP Motion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 27, 2016 , ... Newly created 4Sight Medical Solutions ... the healthcare market. The company's primary focus is on new product introductions, to ... that are necessary to help companies efficiently bring their products to market. , ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... 2016  The Prostate Cancer Foundation (PCF) is pleased to announce ... cures for prostate cancer. Members of the Class of 2016 were selected from ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:6/22/2016)... On Monday, the Department of Homeland Security ... solutions for the Biometric Exit Program. The Request for ... (CBP), explains that CBP intends to add biometrics to ... United States , in order to deter visa ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/20/2016)... -- Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring announced that after exhaustive ... the final acceptance by all three (3) Department ... (MAS) installed. Furthermore, Securus will have contracts for ... October, 2016. MAS distinguishes between legitimate wireless device ...
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
Breaking Biology News(10 mins):